Home > Boards > US Listed > Medical - Equipment >

electroCore, Inc. (ECOR)

ECOR RSS Feed
Add ECOR Price Alert      Hide Sticky   Hide Intro
Moderator: mick, $Pistol Pete$
Search This Board: 
Last Post: 5/10/2022 2:14:12 AM - Followers: 41 - Board type: Free - Posts Today: 0






gammaCore SapphireTM CV (nVNS) receives Emergency Use Authorization (EUA) to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
Learn More

http://www.electrocore.com/

$ECOR Answers to military & veterans questions about migraine & cluster headache



https://www.gammacore.com/for-veterans/how-gammacore-works-va/
https://www.gammacore.com/for-veterans/testimonials-va/
https://www.gammacore.com/for-veterans/faq/

http://www.electrocore.com/aboutus/
http://www.electrocore.com/nVNS/
http://www.electrocore.com/product/
http://www.electrocore.com/future-developments/
http://www.electrocore.com/for-payers/
News Releases
gammaCore SapphireTM CV (nVNS) receives Emergency Use Authorization (EUA) to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
Learn More
Date Title and Summary
Toggle SummaryJuly 30, 2020 electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients
Toggle SummaryJuly 28, 2020 electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia
Toggle SummaryJuly 16, 2020 Correction - electroCore Provides Business Update and Select Financial Guidance
Toggle SummaryJuly 14, 2020 electroCore Provides Business Update and Select Financial Guidance
Toggle SummaryJuly 13, 2020 electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients
Toggle SummaryJuly 9, 2020 electroCore to Participate in Three Upcoming Virtual Investor Conferences
Toggle SummaryMay 29, 2020 electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference
Toggle SummaryMay 14, 2020 electroCore Announces First Quarter Financial Results


 

Emergency Use Authorization (EUA)gammaCore SapphireTM CV (nVNS)
receives EUA to treat patients with known or suspected COVID-19
who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.




https://finviz.com/quote.ashx?t=ECOR

[-chart]finviz.com/chart.ashx?t=ECOR&ty=c&ta=1&p=d&s=l[/chart]




 
Shs Outstand 29.77M
Shs Float 26.32M
Short Float 11.46%
 
Inst Own 19.60%
Debt/Eq  NO DEBT 0.00
Book/sh 0.57
 
Employees 51




$ECOR https://www.otcmarkets.com/stock/ECOR/disclosure

https://www.otcmarkets.com/stock/ECOR/news

https://www.otcmarkets.com/stock/ECOR/security

https://www.otcmarkets.com/stock/ECOR/profile

https://www.otcmarkets.com/stock/ECOR/quote

https://www.otcmarkets.com/stock/ECOR/overview
 
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a
range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated
with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire,
a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis.
The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Period End Date   TTM 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Period Length   12 Months 12 Months 12 Months 12 Months 12 Months
Total Revenue
 
3.24 2.39 0.99  

 

Cost of Revenue
 
1.31 1.16 0.58
Gross Profit
 
1.93 1.23 0.41
Selling, General and Administrative
 
23.69 35.42 42.50
Research and Development
 
4.81 9.90 12.47
Unusual Expense/Income
 
0.46 2.00 0.00
Total Operating Expense
 
30.27 48.48 55.55
Operating Income
 
-27.03 -46.09 -54.55
Interest Income Net
 
0.20 0.97 1.01
Other Income Net
 
-0.01 -0.01 -2.22
Net Income Before Taxes
 
-26.84 -45.13 -55.76
Provision for Income Taxes
 
-1.15 0.02 0.00
Net Income
 
-25.69 -45.15 -55.82
Income Avail. to Common Excl. Extraord.
 
-25.69 -45.15 -55.82
Income Avail. to Common Incl. Extraord.
 
-25.69 -45.15 -55.82
Diluted Average Shares
 
34.99 29.38 29.26
Diluted EPS Excl. Extraord.
 
-0.78660 -1.53669 -1.90761
Diluted EPS Incl. Extraord.
 
-0.78660 -1.53669 -1.9076





 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.

 
what private placement about ????? i see insider buying 
 
https://finviz.com/quote.ashx?t=ecor&ty=c&ta=1&p=d
 
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Errico Thomas J. Director Apr 14 Buy 0.85 176,470 150,000 1,245,450 Apr 16 09:10 PM
Moody Trevor J Director Apr 14 Buy 0.85 116,647 99,150 177,944 Apr 16 09:09 PM
TULLIS JAMES L L Director Apr 14 Buy 0.85 1,764,705 1,499,999 1,764,705 Apr 16 04:24 PM



So discounted shares are being dumped at the market price instant profit for the Gang.. No wonder it cant go up
 
ECOR
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ECOR News: Statement of Changes in Beneficial Ownership (4) 05/18/2022 04:31:32 AM
ECOR News: electroCore to Participate at Upcoming Investor Conferences 05/18/2022 04:00:00 AM
ECOR News: Statement of Changes in Beneficial Ownership (4) 05/17/2022 12:08:08 PM
ECOR News: Maxim Group Sticks to Their Buy Rating for Electrocore (ECOR) 05/07/2022 03:35:44 AM
ECOR News: Quarterly Report (10-q) 05/05/2022 01:09:28 PM
PostSubject
#843  Sticky Note $ECOR ElectroCore Granted FDA Breakthrough Designation for gammaCore $Pistol Pete$ 01/15/22 07:16:04 PM
#385  Sticky Note Regarding your question: "what's sham treatment ?????" MinnieM 07/31/20 07:52:46 PM
#880   ECOR electroCore Inc mick 05/10/22 02:14:12 AM
#879   CEO announces "strong results" in which ECOR continues Polyphemus 05/09/22 10:07:02 AM
#878   ECOR electroCore Inc mick 05/05/22 02:28:59 PM
#877   Thanks for sharing $Pistol Pete$ 05/05/22 02:34:11 AM
#876   ECOR electroCore Inc mick 05/03/22 02:15:43 PM
#875   Watch out - Amended 10K filed May 2. Polyphemus 05/03/22 10:03:01 AM
#874   electroCore Inc (ECOR) mick 05/01/22 04:07:33 PM
#873   yes , i like mick 04/26/22 10:40:09 AM
#872   Trading near 12 mo low, but still above Polyphemus 04/26/22 10:31:45 AM
#871   electroCore Inc (ECOR) mick 04/26/22 10:11:17 AM
#870   Polyphemus, I agree with most everything that you Bigspirit1 04/17/22 11:31:25 AM
#869   Agree with your incisive comment. My estimate Polyphemus 04/12/22 09:55:46 AM
#868   Agreed. Clearly it was a mistake to Bigspirit1 04/07/22 03:43:58 PM
#867   Ran away from it $Pistol Pete$ 04/04/22 09:10:39 PM
#866   5 years since FDA 510(k) on May 17,2017. Polyphemus 04/04/22 10:14:48 AM
#865   yes/ ECOR mick 03/19/22 02:24:54 PM
#864   Another great close today $Pistol Pete$ 03/18/22 11:35:47 PM
#863   Average trade - $209.33. Now only -74% Polyphemus 03/18/22 06:01:08 PM
#862   ECOR electroCore Inc mick 03/18/22 11:12:39 AM
#861   Nice move today $Pistol Pete$ 03/18/22 12:50:17 AM
#860   electroCore Inc (ECOR) mick 03/12/22 04:10:24 PM
#859   Let’s wait and see…just don’t want to miss $Pistol Pete$ 03/12/22 12:02:14 AM
#858   Let's not miss the key points. ECOR Polyphemus 03/11/22 09:41:27 AM
#857   Yes they do has $30m cash on hand $Pistol Pete$ 03/10/22 06:22:20 PM
#856   thank you mick 03/10/22 10:31:02 AM
#855   ECOR responds to the strategic failure of its Polyphemus 03/10/22 10:24:43 AM
#854   electroCore Inc (ECOR) mick 02/06/22 05:24:23 PM
#853   electroCore, Inc. Announces Completion of Enrollment in the mick 02/01/22 12:10:12 PM
#852   YES mick 02/01/22 12:09:53 PM
#851   $ECOR electroCore, Inc. Announces Completion of Enrollment in $Pistol Pete$ 02/01/22 08:11:37 AM
#850   electroCore Inc (ECOR) mick 01/31/22 04:32:21 PM
#849   3 scientific abstracts on the effects of eVNS Polyphemus 01/31/22 11:43:04 AM
#848   electroCore Inc (ECOR) mick 01/19/22 11:07:23 PM
#847   My son made a good score on ECOR longboarder7892 01/19/22 10:28:15 AM
#846   ECOR mick 01/18/22 12:11:03 PM
#845   Sound good $Pistol Pete$ 01/17/22 11:01:24 PM
#844   IMO, for FDA Breakthrough status to entice institutional Polyphemus 01/17/22 12:14:41 PM
#843   $ECOR ElectroCore Granted FDA Breakthrough Designation for gammaCore $Pistol Pete$ 01/15/22 07:16:04 PM
#842   Hopefully institutional investors will push it above $1 $Pistol Pete$ 01/14/22 09:53:49 PM
#841   Volume is up. Current share price is Polyphemus 01/14/22 09:45:30 AM
#840   electroCore Inc (ECOR) mick 01/14/22 03:19:58 AM
#839   THANK YOU electroCore Inc (ECOR) mick 01/13/22 04:47:44 PM
#838   Accumulate happen today $Pistol Pete$ 01/13/22 04:17:23 PM
#837   FDA Breakthrough Device Designation of gammaCore for PTSD Polyphemus 01/13/22 09:26:14 AM
#836   Good to see you here mick. I found NEXT 01/12/22 08:55:58 PM
#835   electroCore Inc (ECOR) mick 01/12/22 06:17:43 PM
#834   electroCore Inc (ECOR) mick 01/12/22 06:17:03 PM
#833   Thanks for the sharing.......... $Pistol Pete$ 01/12/22 05:14:24 PM
#832   Yes we are $Pistol Pete$ 01/12/22 05:12:47 PM
#830   The ideal review time stipulated by the de crudeoil24 01/12/22 02:45:34 PM
PostSubject
Consent Preferences